Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2019

01-04-2019 | PRECLINICAL STUDIES

Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts

Authors: V. S. Pokrovsky, N. Yu Anisimova, D. Zh Davydov, S. V. Bazhenov, N. V. Bulushova, G. B. Zavilgelsky, V. Y. Kotova, I. V. Manukhov

Published in: Investigational New Drugs | Issue 2/2019

Login to get access

Summary

The anti-cancer efficacy of methionine γ-lyase (MGL) from Clostridium sporogenes (C. sporogenes) is described. MGL was active against cancer models in vitro and in vivo. The calculated EC50 values for MGL were 4.4 U/ml for A549, 7.5 U/ml for SK-BR3, 2.4 U/ml for SKOV3, and 0.4 U/ml for MCF7 cells. The combination of doxorubicin (DOX) and MGL was more effective for A549 human lung cancer growth inhibition than either agent alone in vitro and in vivo. MGL reduced the EC50 of doxorubicin from 35.9 μg/mL to 0.01–0.265 μg/mL. The growth inhibitory effect of DOX + MGL on A549 xenografts in vivo was reflective of the results obtained in vitro. The inhibition rate of tumor growth in the combined arm was 57%, significantly higher than that in the doxorubicin (p = 0.033)-alone arm.
Literature
1.
El-Sayed AS (2010) Microbial L-methioninase: production, molecular characterization, and therapeutic applications. Appl Microbiol Biotechnol 86(2):445–467CrossRefPubMed
2.
Cellarier E, Durando X, Vasson MP et al (2003) Methionine dependency and cancer treatment. Cancer Treat Rev 29:488–489CrossRef
3.
Hoffman RM (2015) Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15:21–31CrossRefPubMed
4.
Kreis W, Hession C (1973) Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor. Cancer Res 33:1866–1869PubMed
5.
Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM, Sugita K (1998) Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil and safety of recombinant methioninase. Cancer Res 58:2583–2587PubMed
6.
Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX, Hoffman RM (1999) Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5:2157–2163PubMed
7.
Kokkinakis DM, Wick JB, Zhou Q-X (2002) Metabolic response of normal and malignant tissue to acute and chronic methionine stress in athymic mice bearing human glial tumor xenografts. Chem Res Toxicol 15:1472–1479CrossRefPubMed
8.
Murakami T, Li S, Han Q, Tan Y, Kiyuna T, Igarashi K, Kawaguchi K, Hwang HK, Miyake K, Singh AS, Nelson SD, Dry SM, Li Y, Hiroshima Y, Lwin TM, DeLong J, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM (2017) Recombinant methioninase effectively targets a Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 8:35630–35638PubMedPubMedCentral
9.
Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Kiyuna T, Miyake K, Murakami T, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Eilber FC, Hoffman RM (2017) Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma growth in a patient-derived orthotopic xenograft. Oncotarget 8:85516–85525PubMedPubMedCentral
10.
Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Murakami T, Kiyuna T, Miyake K, Miyake M, Singh AS, Eckardt MA, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Singh SR, Eilber FC, Hoffman RM (2018) Recombinant methioninase in combination with DOX overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Lett 417:168–173CrossRefPubMed
11.
El-Sayed AS, Shouman SA, Nassrat HM (2012) Pharmacokinetics, immunogenicity and anticancer efficiency of aspergillus flavipes L-methioninase. Enzym Microb Technol 51(4):200–210CrossRef
12.
Stern PH, Hoffman RM (1986) Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst (Bethesda) 76:629–639CrossRef
13.
Kokkinakis DM, Schold SCJ, Hori H, Nobori T (1997) Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice. Nutr Cancer 29:195–204CrossRefPubMed
14.
Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, Tan Y, Schold SC (2001) Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61:4017–4023PubMed
15.
Morozova EA, Kulikova VV, Yashin DV, Anufrieva NV, Anisimova NY, Revtovich SV, Kotlov MI, Belyi YF, Pokrovsky VS, Demidkina TV (2013) Kinetic parameters and cytotoxic activity of recombinant methionine γ-Lyase from Clostridium tetani, Clostridium sporogenes, Porphyromonas gingivalis and Citrobacter freundii. Acta Nat 5(3):92–98CrossRef
16.
Studier FW (2005) Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif 41:207–234CrossRefPubMed
17.
Anufrieva NV, Morozova EA, Kulikova VV, Bazhulina NP, Manukhov IV, Degtev DI, Gnuchikh EY, Rodionov AN, Zavilgelsky GB, Demidkina TV (2015) Sulfoxides, analogues of L-methionine and L-cysteine as pro-drugs against gram-positive and gram-negative Bacteria. Acta Nat 7(4):128–135CrossRef
18.
Pokrovskaya MV, Pokrovskiy VS, Aleksandrova SS, Anisimova NY, Andrianov RM, Treschalina EM, Ponomarev GV, Sokolov NN (2012) Recombinant intracellular Rhodospirillum rubrum L-asparaginase with low L-glutaminase activity and antiproliferative effect. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 6(2):123–131CrossRef
19.
Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446CrossRef
20.
Wang WT, Zhao Y, Gao JL et al (2014) Cytotoxicity enhancement in MDA-MB-231 cells by the combination treatment of tetrahydropalmatine and berberine derived from Corydalis yanhusuo. Intercult Ethnopharmacol 3(2):68–72CrossRef
21.
Sidoruk KV, Pokrovsky VS, Borisova AA, Omeljanuk NM, Aleksandrova SS, Pokrovskaya MV, Gladilina JA, Bogush VG, Sokolov NN (2011) Creation of a producent, optimization of expression, and purification of recombinant Yersinia pseudotuberculosis L-asparaginase. Bull Exp Biol Med 152(2):219–223CrossRefPubMed
22.
Pokrovskaya MV, Aleksandrova SS, Pokrovsky VS, Veselovsky AV, Grishin DV, Abakumova OY, Podobed OV, Mishin AA, Zhdanov DD, Sokolov NN (2015) Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis. Mol Biotechnol 57(3):251–264CrossRefPubMed
23.
Pokrovsky VS, Kazanov MD, Dyakov IN, Pokrovskaya MV, Aleksandrova SS (2016) Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. BMC Cancer 16:89CrossRefPubMedPubMedCentral
24.
Sannikova EP, Bulushova NV, Cheperegin SE, Gubaydullin II, Chestukhina GG, Ryabichenko VV, Zalunin IA, Kotlova EK, Konstantinova GE, Kubasova TS, Shtil AA, Pokrovsky VS, Yarotsky SV, Efremov BD, Kozlov DG (2016) The modified heparin-binding L-Asparaginase of Wolinella succinogenes. Mol Biotechnol 58(8–9):528–539CrossRefPubMed
25.
Pokrovsky VS, Treshalina HM, Lukasheva EV, Sedakova LA, Medentzev AG, Arinbasarova AY, Berezov TT (2013) Enzymatic properties and anticancer activity of L-lysine α-oxidase from Trichoderma cf. aureoviride Rifai BKMF-4268D. Anti-Cancer Drugs 24(8):846–851CrossRefPubMed
26.
Babich OO, Pokrovsky VS, Anisimova NY, Sokolov NN, Prosekov AY (2013) Recombinant l-phenylalanine ammonia lyase from Rhodosporidium toruloides as a potential anticancer agent. Biotechnol Appl Biochem 60(3):316–322CrossRefPubMed
27.
Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM (1983) The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117:429–434CrossRef
28.
Hoffman RM, Erbe RW (1976) High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci U S A 73:1523–1527CrossRefPubMedPubMedCentral
29.
Hoffman RM (1984) Altered methionine metabolism, DNA methylation, and oncogene expression in carcinogenesis: a review and synthesis. Biochim Biophys Acta 738:49–87PubMed
30.
Guo H, Herrera H, Groce A, Hoffman RM (1993) Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53:2479–2483PubMed
31.
Morozova EA, Anufrieva NV, Davydov DZ, Komarova MV, Dyakov IN, Rodionov AN, Demidkina TV, Pokrovsky VS (2017) Plasma methionine depletion and pharmacokinetic properties in mice of methionine γ-lyase from Citrobacter freundii, Clostridium tetani and Clostridium sporogenes. Biomed Pharmacother 88:978–984CrossRefPubMed
Metadata
Title
Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts
Authors
V. S. Pokrovsky
N. Yu Anisimova
D. Zh Davydov
S. V. Bazhenov
N. V. Bulushova
G. B. Zavilgelsky
V. Y. Kotova
I. V. Manukhov
Publication date
01-04-2019
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0619-4

Other articles of this Issue 2/2019

Investigational New Drugs 2/2019 Go to the issue

PRECLINICAL STUDIES

Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells

PHASE II STUDIES

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

PHASE II STUDIES

IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study

PHASE I STUDIES

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

PRECLINICAL STUDIES

The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines

PHASE I STUDIES

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits